Estimated 2026 sales: $49.50 billion
2019 sales: $40.17 billion
2019-26 CAGR: 3.03%
After taking the helm at Sanofi last September, CEO Paul Hudson in December unveiled his vision for the drugmaker. It was an ambitious strategy shift: The company would double down in areas where it believes it can succeed, and downsize or exit other fields.
R&D in diabetes and cardiovascular fields would go, for instance, making room for Sanofi to plow resources into cancer, rare diseases, vaccines and other growth prospects.
A big part of that vision is Dupixent, an immunology med already approved in atopic dermatitis, asthma and rhinosinusitis with nasal polyps. The company plans dozens more Dupixent launches in new markets and new uses in the coming years, and aims to reach €10 billion in peak sales.
Meanwhile, Sanofi is also moving to bulk up in oncology, and this year won approval for multiple myeloma Sarclisa. The drug is Sanofi’s first wholly owned oncology medicine to score an FDA approval in a decade, and a medicine that represents a “return to oncology” for the drugmaker, an exec said.
Sanofi is also investing big money into vaccines. In June, for instance, the company committed $554 million toward a new manufacturing facility in eastern France. That move was part of an effort to be better prepared for future pandemics as the world battles COVID-19.
The revamp also means Sanofi is downsizing in areas where it has a rich history, namely diabetes and cardiovascular diseases. The company also said it’s “right-sizing” marketing teams for PCSK9 med Praluent and immunology drug Kevzara.
Since then, Sanofi has revamped its Regeneron pact to focus in on Dupixent, returning certain rights for those medicines to either company. Because Kevzara has generated interest in COVID-19, the partners haven’t immediately split on that medicine.
Hudson has implemented a focus on first-in-class or best-in-class medicines for the company. At a recent R&D day, execs talked about prospects for fitusiran and BIVV01 in hemophilia, rare disease med venglustat, SERD '859 in breast cancer, and the AstraZeneca-partnered nirsevimab in respiratory syncytial virus, among others. The company anticipates submissions for those medicines between 2021 and 2023.
Along with its shift to new areas of focus, Sanofi is working to speed up its R&D group and focus on execution, according to the presentation.
Overall, analysts cited by Evaluate expect Sanofi to post 3% annual growth through 2026, reaching nearly $50 billion in sales that year. It’ll still trail other Big Pharma rivals with that level of sales, but fall comfortably within the top 10.